What is claimed is:

1. A composition comprising a trio of anti-EGFR antibodies comprising a first antibody, a second antibody and a third antibody, wherein (i) the first antibody is, or competes for binding to EGFR with, or binds to the same epitope as, an antibody selected from the group consisting of ca, cb and cc; (ii) the second antibody is, or competes for binding to EGFR with, or binds to the same epitope as, an antibody selected from the group consisting of cd, ce and cf; and (iii) the third antibody is, or competes for binding to EGFR with, or binds to the same epitope as, an antibody selected from the group consisting of cg, ch, ci, cj and ck.

2. The composition of claim 1, wherein (i) the first antibody is, or competes for binding to EGFR with, or binds to the same epitope as, antibody ca (comprising heavy chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 29, 30 and 34, respectively, and light chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 48, 45 and 49, respectively); (ii) the second antibody is, or competes for binding to EGFR with, or binds to the same epitope as, antibody cd (comprising heavy chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 29, 30 and 31, respectively, and light chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 53, 54 and 55, respectively); and (iii) the third antibody is, or competes for binding to EGFR with, or binds to the same epitope as, antibody ch (comprising heavy chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 23, 24 and 26, respectively, and light chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 39, 40 and 42, respectively).

3. Use of the composition of claim 1 or 2 for the manufacture of a medicament for the treatment of a cancer.

4. The use of claim 3, wherein the treatment of the cancer is treatment by combination therapy with an additional medicament that is an anti-cancer agent.

5. The use of Claim 4 wherein the anti-cancer agent comprises a topoisomerase inhibitor.

6. An isolated monoclonal antibody that binds to EGFR extracellular domain and comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 and further comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 13, 14, 15, 16, 17, 19, 20, 21, and 22.

7. An isolated monoclonal antibody that binds to EGFR extracellular domain and comprises a heavy chain variable region and a light chain variable region comprising amino acid sequences selected from the group consisting of:

(a) SEQ ID NO:9 and SEQ ID NO:20, respectively;

(b) SEQ ID NO:10 and SEQ ID NO:21, respectively;

(c) SEQ ID NO:11 and SEQ ID NO:22, respectively;

(d) SEQ ID NO:1 and SEQ ID NO:12, respectively;

(e) SEQ ID NO:2 and SEQ ID NO:13, respectively;

(f) SEQ ID NO:3 and SEQ ID NO:14, respectively;

(g) SEQ ID NO:4 and SEQ ID NO:15, respectively;

(h) SEQ ID NO:5 and SEQ ID NO:16, respectively;

(i) SEQ ID NO:6 and SEQ ID NO:17, respectively; and

(j) SEQ ID NO:8 and SEQ ID NO:19, respectively.

8. An isolated monoclonal antibody which binds EGFR extracellular domain and comprises heavy and light chain CDR3, CDR2, and CDR1, sequences, wherein the heavy and light chain CDR3, CDR2, and CDR1, sequences are selected from:

(a) heavy chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 34, 20, and 29 respectively, and light chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 49, 45, and 48, respectively;

(b) heavy chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 37, 36, and 35, respectively, and light chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 51, 45 and 50, respectively;

(c) heavy chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 38, 36, and 35, respectively, and light chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 52,45, and 48, respectively;

(d) heavy chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 31, 30, and 29, respectively, and light chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 55, 54, and 53, respectively;

(e) heavy chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 32, 30, and 29, respectively, and light chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 56, 54 and 53, respectively;

(f) heavy chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs:33, 30, and 29, respectively, and light chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 56, 54, and 53, respectively;

(g) heavy chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 25, 24, and 23, respectively, and light chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 41, 40, and 39 respectively;

(h) heavy chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 26, 24, and 23, respectively, and light chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 42, 40, and 39, respectively;

(i) heavy chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 27, 24, and 23, respectively, and light chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 43, 40, and 39, respectively;

(j) heavy chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 28, 24, and 23, respectively, and light chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 46, 45, and 44, respectively; and

(k) heavy chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 28, 24, and 23, respectively, and light chain CDR3, CDR2, and CDR1 sequences of SEQ ID NOs: 47, 45, and 44, respectively.

9. An isolated monoclonal antibody that competes for binding to EGFR extracellular domain with, or binds to the same epitope as, any one of the antibodies of claim 7.

10. An isolated antibody of any one of claims 5-9, wherein the antibody is human, chimeric, or humanized.

11. An isolated antibody of any one of claims 5-9 or 5-10, wherein the antibody is selected from the group consisting of a bispecific antibody, immunoconjugate, Fab, Fab'2, ScFv, affibody, avimer, nanobody, and a domain antibody.

12. A composition comprising a pair of antibodies selected from the pairs set forth in Table II or Table III, wherein each antibody is an antibody of any one of claims 5-9 or 5-11.

13. A composition comprising a trio of antibodies selected from the trios set forth in Table IV or Table V, wherein each antibody is an antibody of any one of claims 5-9 or 5-11.

14. The composition of any one of claims 5-9 or 12 or 13, wherein each of the antibodies comprised by the composition binds to EGFR with a K_D of better than 100nm.

15. The composition of any one of claims 5-9 or 12, or 13, or 14, wherein the composition exhibits at least one of the following properties:

(a) inhibition of AKT phosphorylation or ERK phosphorylation, as measured in a cell-based *in vitro* assay;

(b) inhibition of the growth of tumor cells expressing EGFR *in vitro*;

(c) inhibition of the growth of tumor cells expressing EGFR in a xenograft model *in vivo*;

(d) inhibition of ligand binding to EGFR extracellular domain *in vitro*;

(e) inhibition of EGFR dimerization *in vitro*; or.

(f) downregulation of EGFR on cell surfaces *in vitro*.

16. The composition of claim 15, wherein the inhibition is additive or synergistc as compared to a preparation comprising an individual antibody comprised by

the composition in an amount (in moles) equivalent to the total amount (in moles) of combined antibodies in the composition.

17. A composition comprising two or more antibodies, wherein two of the two or more antibodies are selected from the group consisting of:

(a) antibody ca or an antibody that competes for binding to EGFR with, or binds to the same epitope as antibody ca, and antibody cd, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody cd;

(b) antibody ca or an antibody that competes for binding to EGFR with, or binds to the same epitope as antibody ca, and antibody ce, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody ce;

(c) antibody ca or an antibody that competes for binding to EGFR with, or binds to the same epitope as antibody ca, and antibody cf, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody cf;

(d) antibody ca or an antibody that competes for binding to EGFR with, or binds to the same epitope as antibody ca and antibody cg, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody cg;

(e) antibody ca or an antibody that competes for binding to EGFR with, or binds to the same epitope as antibody ca and antibody ch, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody ch;

(f) antibody ca or an antibody that competes for binding to EGFR with, or binds to the same epitope as antibody ca and antibody ci, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody ci;

(g) antibody ca or an antibody that competes for binding to EGFR with, or binds to the same epitope as antibody ca and antibody cj, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody cj;

(h) antibody ca or an antibody that competes for binding to EGFR with, or binds to the same epitope as antibody ca and antibody ck, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody ck;

(i) antibody cb or an antibody that competes for binding to EGFR with, or binds to the same epitope as antibody cb and antibody cd, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody cd;

(j) antibody cb or an antibody that competes for binding to EGFR with, or binds to the same epitope as antibody antibody ca and antibody ce, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody ce;

(k) antibody cb or an antibody that competes for binding to EGFR with, or binds to the same epitope as antibody cb and antibody cf, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody cf;

(l) antibody cb or an antibody that competes for binding to EGFR with antibody cb and antibody cg, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody cg;

(m) antibody cb or an antibody that competes for binding to EGFR with antibody cb and antibody ch, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody ch;

(n) antibody cb or an antibody that competes for binding to EGFR with antibody cb and antibody ci, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody ci;

(o) antibody cb or an antibody that competes for binding to EGFR with antibody cb and antibody cj, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody cj;

(p) antibody cb or an antibody that competes for binding to EGFR with antibody cb and antibody ck, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody ck;

(q) antibody cc or an antibody that competes for binding to EGFR with antibody cc and antibody cd, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody cd;

(r) antibody cc or an antibody that competes for binding to EGFR with antibody cc and antibody ce, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody ce;

(s) antibody cc or an antibody that competes for binding to EGFR with antibody cc and antibody cf, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody cf;

(t) antibody cc or an antibody that competes for binding to EGFR with antibody cc and antibody cg, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody cg;

(u) antibody cc or an antibody that competes for binding to EGFR with antibody cc and antibody ch, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody ch.

(v) antibody cc or an antibody that competes for binding to EGFR with antibody cc and antibody ci, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody ci;

(w) antibody cc or an antibody that competes for binding to EGFR with antibody cc and antibody cj, or an antibody that competes for binding to EGFR with, or binds to the same epitope as antibody cj;

(x) antibody cc or an antibody that competes for binding to EGFR with antibody cc and antibody ck, or an antibody that competes for binding to EGFR with, or binds to the same epitope as, antibody ck.

18. The composition of any one of claims 12-16, wherein the antibodies are:

(a) selected from the group consisting of antibodies va and vd, and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies va and vd; or

(b) the group consisting of antibodies va and ve, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies va and ve; or

(c) the group consisting of antibodies va and vf, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies va and vf;

(d) the group consisting of antibodies va and vg, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies va and vg;

(e) the group consisting of antibodies va and vh, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies va and vh;

(f) the group consisting of antibodies va and vi, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies va and vi;

(h) the group consisting of antibodies va and vj, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies va and vj;

(i) the group consisting of antibodies vb and vd, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies va and vi;

(j) the group consisting of antibodies vb and ve, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vb and ve;

(k) the group consisting of antibodies vb and vf, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vb and vf;

(l) the group consisting of antibodies vb and vg, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vb and vg;

(m) the group consisting of antibodies vb and vh, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vb and vh;

(n) the group consisting of antibodies vb and vi or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vb and vi;

(o) the group consisting of antibodies vb and vj, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vb and vj;

(p) the group consisting of antibodies vc and vd, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vc and vd;

(q) the group consisting of antibodies vc and ve, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vc and ve;

(r) the group consisting of antibodies vc and vf, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vc and vf;

(s) the group consisting of antibodies vc and vg, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vc and vg;

(t) the group consisting of antibodies vc and vh, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vc and vh;

(u) the group consisting of antibodies vc and vi, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vc and vi; and

(v) the group consisting of antibodies vc and vj, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vc and vj.

19. The composition of any one of claims 12-18, further comprising a third antibody.

20. The composition of claim 19, wherein the antibodies are:

(a) the group consisting of antibodies ca, cg, cd, and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies ca, cg, and cd;

(b) the group consisting of antibodies ca, cg, ce and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies ca, cg, and ce;

(c) the group consisting of antibodies ca, cg, cf, and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies ca, cg, and cf;

(d) the group consisting of antibodies ca, ch, cd and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies ca, ch, and cd;

(e) the group consisting of antibodies ca, ch, ce, and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies ca, ch, and ce;

(f) antibodiesca, ch, cf and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies ca, ch, and cf;

(g) the group consisting of antibodies ca, ci, cd, and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies ca, ci, and cd;

(h) the group consisting of antibodies ca, ci, ce and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies ca, ci, and ce;

(i) the group consisting of antibodies ca, ci, cf, and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies ca, ci, and cf;

(j) the group consisting of antibodies ca, cj, cd and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies ca, cj, and cd;

(k) the group consisting of antibodies ca, cj, ce, and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies ca, cj, and ce;

(l) the group consisting of antibodies ca, cj, cf and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies ca, cj, and cf;

(m) the group consisting of antibodies ca, ck, cd, and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies ca, ck, and cd;

(n) the group consisting of antibodies ca, ck, ce and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies ca, ck, and ce;

(o) the group consisting of antibodies ca, ck, cf, and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies ca, ck, and cf;

(p) the group consisting of antibodies cb, cg, cd and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cb, cg, and cd;

(q) the group consisting of antibodies cb, cg, ce, and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cb, cg, and ce;

(r) the group consisting of antibodies cb, cg, cf and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cb, cg, and cf;

(s) the group consisting of antibodies cb, ch, cd and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cb, ch, and cd;

(t) the group consisting of antibodies cb, ch, ce and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cb, ch, and ce;

(u) the group consisting of antibodies cb, ch, cf and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cb, ch, and cf;

(v) the group consisting of antibodies cb, ci, cd and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cb, ci, and cd;

(w) the group consisting of antibodies cb, ci, ce and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cb, ci, and ce;

(x) the group consisting of antibodies cb, ci, cf and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cb, ci, and cf;

(y) the group consisting of antibodies cb, cj, cd and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cb, cj, and cd;

(z) the group consisting of antibodies cb, cj, ce and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cb, cj, and ce;

(aa) the group consisting of antibodies cb, cj, cf and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cb, cj, and cf;

(bb) the group consisting of antibodies cb, ck, cd and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cb, ck, and cd;

(cc) the group consisting of antibodies cb, ck, ce and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cb, ck, and ce;

(cc) the group consisting of antibodies cb, ck, cf and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cb, ck, and cf;

(dd) the group consisting of antibodies cc, cg, cd and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cc, cg, and cd;

(ee) the group consisting of antibodies cc, cg, ce and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cc, cg, and ce;

(ff) the group consisting of antibodies cc, cg, cf and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cc, cg, and cf;

(gg) the group consisting of antibodies cc, ch, cd and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cc, ch, and cd;

(hh) the group consisting of antibodies cc, ch, ce and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cc, ch, and ce;

(ii) the group consisting of antibodies cc, ch, cf and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cc, ch, and cf;

(jj) the group consisting of antibodies cc, ci, cd and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cc, ci, and cd;

(kk) the group consisting of antibodies cc, ci, ce and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cc, ci, and ce;

(ll) the group consisting of antibodies cc, ci, cf and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cc, ci, and cf;

(mm) the group consisting of antibodies cc, cj, cd and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cc, cj, and cd;

(nn) the group consisting of antibodies cc, cj, ce and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cc, cj, and ce;

(oo) the group consisting of antibodies cc, cj, cf and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cc, cj, and cf;

(pp) the group consisting of antibodies cc, ck, cd and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cc, ck, and cd;

(qq) the group consisting of antibodies cc, ck, ce and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cc, ck, and ce; and

(rr) the group consisting of antibodies cc, ck, cf and antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies cc, ck, and cf.

21. The composition of claim 15, wherein the antibodies are:

(a) antibodies va, vi, vd, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies va, vi, and vd;

(b) antibodies va, vi, ve, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies va, vi, and ve;

(c) antibodies va, vi, vf, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies va, vi, and vf;

(d) antibodies va, vj, vg, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies va, vi, and vg;

(e) antibodies va, vj, vh, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies va, vi, and vh;

(f) antibodies va, vj, vd, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies va, vj, and vd;

(g) antibodies va, vj, ve, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies va, vi, and ve;

(h) antibodies va, vj, vf, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies va, vi, and vf;

(i) antibodies va, vj, vg, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies va, vj, and vg;

(j) antibodies va, vj, vh, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies va, vj, and vh;

(k) antibodies vb, vi, vd, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vb, vi, and vd;

(l) antibodies vb, vi, ve, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vb, vi, and ve;

(m) antibodies vb, vi, vf, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vb, vi, and vf;

(n) antibodies vb, vi, vg, or antibodies which compete for binding to EGFR wit, or bind to the same epitope as,h antibodies vb, vi, and vg;

(o) antibodies vb, vi, vh, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vb, vi, and vh;

(p) antibodies vb, vj, vd, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vb, vj, and vd;

(q) antibodies vb, vj, ve, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vb, vj, and ve;

(r) antibodies vb, vj, vf, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vb, vj, and vf;

(s) antibodies vb, vj, vg, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vb, vj, and vg;

(t) antibodies vb, vj, vh, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vb, vj, and vh;

(u) antibodies vc, vi, vd, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vc, vi, and vd;

(v) antibodies vc, vi, ve, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vc, vi, and ve;

(w) antibodies vc, vi, vf, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vc, vi, and vf;

(x) antibodies vc, vi, vg, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vc, vi, and vg;

(y) antibodies vc, vi, vh, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vc, vi, and vh;

(z) antibodies vc, vj, vd, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vc, vj, and vd;

(aa) antibodies vc, vj, ve, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vc, vj, and ve;

(bb) antibodies vc, vj, vf, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vc, vj, and vf;

(cc) antibodies vc, vj, vg, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vc, vj, and vg; or

(dd) antibodies vc, vj, vh, or antibodies which compete for binding to EGFR with, or bind to the same epitope as, antibodies vc, vj, and vh.

22. Use of a composition of any one of claims 8-21, for the manufacture of a medicament for the treatment of a cancer by combination therapy with an additional anti-cancer agent.

23. The composition of claim 22, wherein the additional anti-cancer agent comprises a topoisomerase inhibitor.

24. A kit comprising the composition of any one of claims 8-23 in a container.

25. The kit of claim 24, wherein the container contains the composition in a single vial.

26. A method for selecting a combination of monoclonal antibodies, each of which binds to EGFR extracellular domain, comprising selecting at least two antibodies which each have an IC90 of better than 80nM for inhibiting EGFR-mediated signaling and which do not compete with each other for binding to EGFR extracellular domain and which each exhibit at least one of the following properties:

(i) inhibition of the growth of cells expressing EGFR in a xenograft model *in vivo*;

(ii) inhibition of ligand binding to EGFR extracellular domain *in vitro*;

(iii) inhibition of EGFR dimerization *in vitro*; or

(iv) downregulation of EGFR on cell surfaces *in vitro*.

(v) inhibition of AKT phosphorylation or ERK phosphorylation, as measured in a cell-based *in vitro* assay

Claims:

1. A composition comprising a trio of anti-EGFR antibodies comprising a first monoclonal antibody, a second monoclonal antibody and a third monoclonal antibody, wherein (i) the first antibody is or binds to the same epitope as, antibody ca (comprising heavy chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 29, 30 and 34, respectively, and light chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 48, 45 and 49, respectively); (ii) the second antibody is or binds to the same epitope as, antibody cd (comprising heavy chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 29, 30 and 31, respectively, and light chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 53, 54 and 55, respectively); and (iii) the third antibody is or binds to the same epitope as, antibody ch (comprising heavy chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 23, 24 and 26, respectively, and light chain CDRs 1, 2 and 3 set forth in SEQ ID NOs: 39, 40 and 42, respectively).

2. A monoclonal antibody of claim 1, wherein the antibody is selected from the group consisting of a bispecific antibody, immunoconjugate, Fab, Fab'2, and ScFv.

3. A composition comprising a trio of antibodies of claim 1, wherein each antibody of the trio is an IgGl, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgAsec, IgD, or IgE.

4. The composition of claim 1, wherein each of the antibodies comprised by the composition binds to EGFR with a K_D of 10^7 to 10^{12} M^{-1}.

5. The composition of claim 1, wherein the composition exhibits at least one of the following properties:

(a) inhibition of AKT phosphorylation or ERK phosphorylation, as measured in a cell-based *in vitro* assay;

(b) inhibition of the growth of tumor cells expressing EGFR *in vitro;*

(c) inhibition of the growth of tumor cells expressing EGFR in a xenograft model *in vivo;*

(d) inhibition of ligand binding to EGFR extracellular domain *in vitro;*

(e) inhibition of EGFR dimerization *in vitro;* or.

(f) downregulation of EGFR on cell surfaces *in vitro.*

6. The composition of claim 5, wherein the inhibition or downregulation is additive or synergistc as compared to a preparation comprising an individual antibody comprised by the composition in an amount (in moles) equivalent to the total amount (in moles) of combined antibodies in the composition.

7. A kit comprising the composition of claim 1 in a container.